Literature DB >> 33865147

Response to targeted cognitive training may be neuroprotective in patients with early schizophrenia.

Ian S Ramsay1, Susanna Fryer2, Brian J Roach2, Alison Boos2, Melissa Fisher3, Rachel Loewy2, Judith M Ford2, Sophia Vinogradov3, Daniel H Mathalon2.   

Abstract

Individuals with schizophrenia exhibit widespread cortical thinning associated with illness severity and deficits in cognition. However, intact cortical thickness (CTh) may serve as a protective factor. The current study sought to examine changes in CTh in response to auditory targeted cognitive training (TCT) in individuals with recent onset schizophrenia. Participants underwent MRI scanning and a cognitive assessment before and after being randomly assigned to 40 h of either TCT (N = 21) or a computer games control condition (CG; N = 22) over 16 weeks. Groups did not differ at baseline on demographic variables or measures of CTh. At the level of group averages, neither group showed significant pre-post changes in CTh in any brain region. However, changes in CTh related to individual differences in treatment outcome, as improved global cognition in the TCT group corresponded to reduced cortical thinning in frontal, temporal, parietal, and occipital lobes. These relationships were not observed in the CG group. The current findings suggest that TCT may be neuroprotective in early schizophrenia, such that individuals who improved in response to training also showed a reduction in cortical thinning that may be otherwise hastened due to age and illness.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cognition; Cognitive training; Cortical thickness; Early schizophrenia; Structural MRI

Mesh:

Year:  2021        PMID: 33865147      PMCID: PMC8137670          DOI: 10.1016/j.pscychresns.2021.111285

Source DB:  PubMed          Journal:  Psychiatry Res Neuroimaging        ISSN: 0925-4927            Impact factor:   2.493


  44 in total

1.  Cortical thickness in neuropsychologically near-normal schizophrenia.

Authors:  Derin J Cobia; John G Csernansky; Lei Wang
Journal:  Schizophr Res       Date:  2011-10-07       Impact factor: 4.939

2.  Cortical thickness in regions of frontal and temporal lobes is associated with responsiveness to cognitive remediation therapy in schizophrenia.

Authors:  Rafael Penadés; Nuria Pujol; Rosa Catalán; Guillem Masana; Clemente García-Rizo; Nuria Bargalló; Alexandre González-Rodríguez; Dídac Vidal-Piñeiro; Miquel Bernardo; Carme Junqué
Journal:  Schizophr Res       Date:  2016-01-15       Impact factor: 4.939

3.  Associations of cortical thickness and cognition in patients with schizophrenia and healthy controls.

Authors:  Stefan Ehrlich; Stefan Brauns; Anastasia Yendiki; Beng-Choon Ho; Vince Calhoun; S Charles Schulz; Randy L Gollub; Scott R Sponheim
Journal:  Schizophr Bull       Date:  2011-03-24       Impact factor: 9.306

4.  Neurophysiologic measures of target engagement predict response to auditory-based cognitive training in treatment refractory schizophrenia.

Authors:  William C Hochberger; Yash B Joshi; Michael L Thomas; Wendy Zhang; Andrew W Bismark; Emily B H Treichler; Melissa Tarasenko; John Nungaray; Joyce Sprock; Lauren Cardoso; Neal Swerdlow; Gregory A Light
Journal:  Neuropsychopharmacology       Date:  2018-10-30       Impact factor: 7.853

5.  Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine.

Authors:  Roberto Roiz-Santiáñez; Diana Tordesillas-Gutiérrez; Victor Ortíz-García de la Foz; Rosa Ayesa-Arriola; Agustín Gutiérrez; Rafael Tabarés-Seisdedos; José Luis Vázquez-Barquero; Benedicto Crespo-Facorro
Journal:  Schizophr Res       Date:  2012-08-11       Impact factor: 4.939

6.  Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial.

Authors:  Shaun M Eack; Gerard E Hogarty; Raymond Y Cho; Konasale M R Prasad; Deborah P Greenwald; Susan S Hogarty; Matcheri S Keshavan
Journal:  Arch Gen Psychiatry       Date:  2010-05-03

7.  Increased global cognition correlates with increased thalamo-temporal connectivity in response to targeted cognitive training for recent onset schizophrenia.

Authors:  Ian S Ramsay; Brian J Roach; Susanna Fryer; Melissa Fisher; Rachel Loewy; Judith M Ford; Sophia Vinogradov; Daniel H Mathalon
Journal:  Schizophr Res       Date:  2020-01-29       Impact factor: 4.939

8.  Measuring the capacity for auditory system plasticity: An examination of performance gains during initial exposure to auditory-targeted cognitive training in schizophrenia.

Authors:  Melissa Tarasenko; Veronica B Perez; Sean T Pianka; Sophia Vinogradov; David L Braff; Neal R Swerdlow; Gregory A Light
Journal:  Schizophr Res       Date:  2016-02-02       Impact factor: 4.939

Review 9.  Effect of aerobic exercise on hippocampal volume in humans: A systematic review and meta-analysis.

Authors:  Joseph Firth; Brendon Stubbs; Davy Vancampfort; Felipe Schuch; Jim Lagopoulos; Simon Rosenbaum; Philip B Ward
Journal:  Neuroimage       Date:  2017-11-04       Impact factor: 6.556

10.  Neurocognitive deficit in schizophrenia: a quantitative review of the evidence.

Authors:  R W Heinrichs; K K Zakzanis
Journal:  Neuropsychology       Date:  1998-07       Impact factor: 3.295

View more
  2 in total

Review 1.  Synaptic plasticity and mental health: methods, challenges and opportunities.

Authors:  Lawrence G Appelbaum; Mohammad Ali Shenasa; Louise Stolz; Zafiris Daskalakis
Journal:  Neuropsychopharmacology       Date:  2022-07-09       Impact factor: 7.853

2.  Durable Cognitive Gains and Symptom Improvement Are Observed in Individuals With Recent-Onset Schizophrenia 6 Months After a Randomized Trial of Auditory Training Completed Remotely.

Authors:  Rachel Loewy; Melissa Fisher; Sisi Ma; Cameron Carter; J Daniel Ragland; Tara A Niendam; Barbara Stuart; Danielle Schlosser; Felix Amirfathi; Seghel Yohannes; Sophia Vinogradov
Journal:  Schizophr Bull       Date:  2022-01-21       Impact factor: 7.348

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.